Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 21;9(7):933.
doi: 10.3390/children9070933.

Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action

Affiliations
Review

Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action

Leslee T Belzer et al. Children (Basel). .

Abstract

Rare diseases (RD) affect children, adolescents, and their families infrequently, but with a significant impact. The diagnostic odyssey undertaken as part of having a child with RD is immense and carries with it practical, emotional, relational, and contextual issues that are not well understood. Children with RD often have chronic and complex medical conditions requiring a complicated milieu of care by numerous clinical caregivers. They may feel isolated and may feel stigmas in settings of education, employment, and the workplace, or a lack a social support or understanding. Some parents report facing similar loneliness amidst a veritable medicalization of their homes and family lives. We searched the literature on psychosocial considerations for children with rare diseases in PubMed and Google Scholar in English until 15 April 2022, excluding publications unavailable in full text. The results examine RD and their psychosocial ramifications for children, families, and the healthcare system. The domains of the home, school, community, and medical care are addressed, as are the implications of RD management as children transition to adulthood. Matters of relevant healthcare, public policies, and more sophisticated translational research that addresses the intersectionality of identities among RD are proposed. Recommendations for interventions and supportive care in the aforementioned domains are provided while emphasizing calls to action for families, clinicians, investigators, and advocacy agents as we work toward establishing evidence-based care for children with RD.

Keywords: advocacy; care coordination; children; families; medical complexity; policy; psychosocial; rare disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Photo Captions: #RareDisease #RareIsntRare; (b) Miya’s Story [14].
Figure 2
Figure 2
The Expert Medical Parent [14].
Figure 3
Figure 3
A Parent Voice: Calls to action that Ryan values most for Miya [14].
Figure 4
Figure 4
Care map created by the mother of a child with medical complexity to pictorially represent aspects of the care her son requires to be coordinated. Used with permission from Cristin Lind, http://www.childrenshospital.org/integrated-care-program/care-mapping accessed on 4 December 2021.

Similar articles

Cited by

References

    1. Richter T., Nestler-Parr S., Babela R., Khan Z.M., Tesoro T., Molsen E., Hughes D. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–914. doi: 10.1016/j.jval.2015.05.008. - DOI - PubMed
    1. Thomas S., Caplan A. The Orphan Drug Act Revisited. JAMA. 2019;321:833–834. doi: 10.1001/jama.2019.0290. - DOI - PubMed
    1. Schuller Y., Gispen-de Wied C., Hollak C.E.M., Leufkens H.G.M., Stoyanova-Beninska V. Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis. J. Clin. Pharmacol. 2019;59:229–244. doi: 10.1002/jcph.1304. - DOI - PMC - PubMed
    1. Harada K., Toriyabe K., Ono S. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval. J. Clin. Phamacol. 2020;60:117–124. doi: 10.1002/jcph.1501. - DOI - PMC - PubMed
    1. Palacios S.A., Palacios M.G., Palacios R.F. The impact of our fight. Cancer Rep. 2021;5:1–5. doi: 10.1002/cnr2.1563. - DOI - PubMed

LinkOut - more resources